About the institute

Institute for cell-focused therapy in gynaecology

The focus of our scientific activity has increasingly developed in the direction of cell-oriented, causal therapy, especially in the field of gynecology. Another long-term focus is the therapy of menopausal complaints with the standardized red clover extract MF11RCE^®.

The following points can be mentioned in this context:

Cell therapy for oncological diseases

Despite all the successes, classical cancer therapy, i.e. surgery, chemotherapy and radiotherapy, has so far brought no resounding results. A new therapeutic approach with first successes is regarded as a scientific innovative fourth path to cancer control: the modulation of the body’s natural defenses, the activation of the immune system. The side effects of the established cancer therapies are enormous and the success is rarely long-term. Only if the body is stimulated to mobilize its own cancer control mechanisms can a sustained healing be possible. Cellular immunotherapy is intended to help the body to do just that, and is therefore a logical complement to classical cancer therapy. Cellular immunotherapy has comparatively few side effects and thus represents a significant improvement in the quality of life of cancer patients.

Dendritic cells are cells of the immune system whose function is antigen processing and antigen presentation of structures recognized as alien. In healthy people, the immune system protects against pathogens such as bacteria, viruses, but also cancer cells. A pathological multiplication of cancer cells usually activates the immune system with the involvement of the dendritic cells and the body’s own defense starts its fight against the cells recognized as hostile. In immunotherapy, autologous (corporeal) dendritic cells are fed to the body in order to stimulate and support the body-specific mechanism of cancer control. Our department has already carried out the first somatic multicentre phase I gene therapy trial in advanced ovarian cancer in Austria (EudraCT Number: 2008-003837-26)

MF11RCE^®-Isoflavones in menopausal complaints

In the discussion of menopausal symptoms, there are two central aspects: Is a treatment in principle risky to health? Are menopausal complaints a natural phase of life or a cause of reduced quality of life and later diseases? Research has not yet clearly answered, but it is confirmed that an early, individualized therapy has a distinct advantage.

Amongst other things, our long-term research showed that MF11RCE^®-Isoflavones considerably reduce menopausal complaints without side effects. MF11RCE^® thus appears to be a very suitable first-line therapy for menopausal complaints and, based on its effectiveness as a “selective estrogen receptor modulator” (SERM), forms the ideal prerequisites to also complement a synthetic estrogen.